The Human Variable 

Infection-associated chronic conditions (IACCs), including Long COVID, ME/CFS, post-treatment Lyme disease syndrome (PTLDS), and related post-infectious syndromes, present a persistent challenge to conventional medical workflows. These conditions are multi-system, fluctuating, and temporally delayed, with symptom expression shaped by environmental exposures, autonomic regulation, immune reactivity, hormonal state, and cumulative demand.

The CYNAERA Primary Chronic Trigger (PCT) framework embeds PEM as a probability-weighted conversion event inside a prevalence model that accounts for viral exposure, environmental load, climate volatility, and recovery suppression. Modeled remission rises from historical 12–18 percent toward 35–50 percent under PEM-aware, terrain-timed designs, with early-intervention subsets reaching 42–60 percent in best-case conditions.

Infection-associated chronic conditions (IACCs) describe a single clinical terrain that appears under many labels—Long COVID, ME/CFS, POTS, MCAS, hEDS overlap, and post-infectious states following EBV, H1N1, Lyme, and Ebola. Triggers differ; downstream biology converges. Across cohorts, patients show immune dysregulation, autonomic instability, mitochondrial hypometabolism, mast-cell mediator sensitivity, connective-tissue fragility, and chronic neuroinflammation.

The CYNAERA Primary Chronic Trigger (PCT) framework embeds PEM as a probability-weighted conversion event inside a prevalence model that accounts for viral exposure, environmental load, climate volatility, and recovery suppression. Modeled remission rises from historical 12–18 percent toward 35–50 percent under PEM-aware, terrain-timed designs, with early-intervention subsets reaching 42–60 percent in best-case conditions.

Contrary to the conventional framing of remission as spontaneous or unachievable, this framework presents remission as a predictable biological outcome, emerging from synchronized interventions across immune, hormonal, mitochondrial, and environmental axes. The CYNAERA Remission Pathway™ outlines a five-phase stabilization and recovery model, while the STAIR: Stable Method™ offers pre-intervention protection for hypersensitive subgroups, including those with mast cell reacti

This future ready framework was built from real world data, patient-led insights and cutting-edge biomarker science. 35–50 million Americans. 25–30% global prevalence. $1 trillion annual impact. The world can’t afford diagnostics that guess, it needs diagnostics that know. Read the groundbreaking Composite Diagnostic Fingerprint for Long COVID, authored by patient-turned-subject matter expert Cynthia Adinig. Nobel Prize worthy thinking. Welcome to CYNAERA. Where technology m